Fragilis Monoclonal Antibody

$Lane 1: NCI-H460 cell lysates; Lane 2: HepG2 cell lysates probed with Fragilis Monoclonal Antibody, Unconjugated (bsm-51629M) at 1:4000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: NCI-H460 cell lysates; Lane 2: HepG2 cell lysates probed with Fragilis Monoclonal Antibody, Unconjugated (bsm-51629M) at 1:4000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

Predicted Reactivity

Human

Overview
Catalog #	bsm-51629M
Product Name	Fragilis Monoclonal Antibody
Applications	WB
Predicted Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	KLH conjugated synthetic peptide derived from human Fragilis
Immunogen Range	21-133/133
Clonality	Monoclonal
Clone #	S12F3
Concentration	0.5ug/ul
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	10410
Swiss Prot	Q01628
Subcellular location	Cytoplasm, Cell membrane
Synonyms	1 8U; Ifitm 3; IFITM3; IFM3_HUMAN; Interferon induced transmembrane protein 3 (1 8U); Interferon Induced Transmembrane Protein 3; Interferon inducible; Interferon inducible protein 1 8U; Interferon Inducible Protein 15; Interferon Inducible Protein Homolog; Interferon-induced transmembrane protein 3; Interferon-inducible protein 1-8U; IP15.
Background	IFN-induced antiviral protein that mediates cellular innate immunity to at least three major human pathogens, namely influenza A H1N1 virus, West Nile virus (WNV), and dengue virus (WNV), by inhibiting the early step(s) of replication.
Application Dilution
WB	=1:500-2000Ôºå